Physician profile
Michael Diaz
NPI 1730229584
$908.25
in general payments reported to CMS, 2019-2025
19 companies · $88.05 in 2025
The $88.05 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $19.58 · 2021: $161 · 2022: $91.81 · 2023: $211 · 2024: $212 · 2025: $88.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $154.83 | 2023-2025 | Vpriv |
| Lilly USA, LLC | $149.63 | 2021-2024 | Jardiance, Mounjaro, Kisunla |
| Alexion Pharmaceuticals, INC. | $124.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $81.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.49 | 2022-2024 | Jardiance |
| Pfizer INC. | $45.31 | 2024 | |
| Xeris Pharmaceuticals, INC. | $35.20 | 2023-2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $32.63 | 2023 | Nuzyra |
| Amgen INC. | $28.44 | 2021 | |
| Incyte Corporation | $26.49 | 2025 | Monjuvi |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.58 | 2020 | |
| Genzyme Corporation | $19.51 | 2023 | |
| Ironwood Pharmaceuticals, INC | $19.09 | 2021 | |
| Antares Pharma, INC. | $16.49 | 2023 | Nocdurna, Tlando, Xyosted |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $15.59 | 2024 | Cologuard Collection Kit |
| Taiho Oncology, INC. | $15.16 | 2025 | |
| Amneal Pharmaceuticals LLC | $15.13 | 2022 | |
| Novo Nordisk INC | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.